New shot form of cancer drug tested in 142 patients
NCT ID NCT05017012
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how the shot felt at the injection site.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bradfordhill ( Site 0100)
Santiago, Region M. de Santiago, 8420383, Chile
-
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 0051)
Port Elizabeth, Eastern Cape, 6055, South Africa
-
Cancercare Rondebosch Oncology-Clinical trials ( Site 0055)
Rondebosch, Western Cape, 7700, South Africa
-
Cape Town Oncology Trials ( Site 0050)
Cape Town, Western Cape, 7570, South Africa
-
FALP-UIDO ( Site 0101)
Santiago, Region M. de Santiago, 7500921, Chile
-
HOSPITAL CLÍNIC DE BARCELONA-Department of Medical Oncology ( Site 0043)
Barcelona, Catalonia, 08036, Spain
-
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0040)
Madrid, Madrid, Comunidad de, 28009, Spain
-
Hospital Universitario Virgen de la Victoria-Phase I Trials Unit ( Site 0042)
Málaga, Andalusia, 29010, Spain
-
James Lind Centro de Investigación del Cáncer ( Site 0102)
Temuco, Araucania, 4800827, Chile
-
Kansai Medical University Hospital ( Site 0112)
Hirakata, Osaka, 573-1191, Japan
-
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0052)
Pretoria, Gauteng, 0181, South Africa
-
Magyar Honvedseg Egeszsegugyi Kozpont-Onkologiai Osztaly ( Site 0020)
Budapest, 1062, Hungary
-
Medical Oncology Centre of Rosebank ( Site 0058)
Johannesburg, Gauteng, 2196, South Africa
-
National Hospital Organization Kyushu Cancer Center ( Site 0114)
Fukuoka, 811-1395, Japan
-
Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0021)
Budapest, Pest County, 1122, Hungary
-
Osaka International Cancer Institute ( Site 0113)
Osaka, 541-8567, Japan
-
Saitama Prefectural Cancer Center ( Site 0110)
Ina-machi, Saitama, 362-0806, Japan
-
Samsung Medical Center ( Site 0063)
Seoul, 06351, South Korea
-
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0053)
Sandton, Gauteng, 2196, South Africa
-
Severance Hospital, Yonsei University Health System ( Site 0062)
Seoul, 03722, South Korea
-
Shizuoka Cancer Center ( Site 0111)
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan
-
Steve Biko Academic Hospital-Medical Oncology ( Site 0057)
Pretoria, Gauteng, 0001, South Africa